A 12-year-old boy with a severe form of muscular dystrophy has said it is "cruel" that a new drug is not being made available ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

—Surveys of caregivers and health care providers reveal gaps in screening and management of neuropsychiatric and neurodevelopmental symptoms among patients with Duchenne muscular dystrophy in ...

Less than half of patients had undergone bone monitoring, suggesting a need for better clinical guidance and management of ...

Older age, presence of scoliosis, and other factors were associated with lower predicted forced vital capacity in patients with Duchenne muscular dystrophy using non-invasive ventilation.

Muscular dystrophy is a disease caused by a genetic mutation. The muscles of muscular dystrophy patients weaken.. | Genetics And Genomics ...

Its expansion is attributed to the treatment of ambulatory DMD patients. The Duchenne muscular dystrophy (DMD) market across ...

Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...